NCT Number: NCT00000508
Stanford Coronary Risk Intervention Project (SCRIP)
To determine whether modification of risk factors altered the rate of progression of coronary artery disease in arteries with mild atherosclerosis and no mechanical intervention in patients who had coronary bypass surgery or percutaneous transluminal coronary angioplasty (PTCA).
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–75 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
About this study
BACKGROUND:
Because of difficulties with quantitative measurement and with feasibility of follow-up, few controlled studies prior to SCRIP had been completed to determine the impact of risk factor modification directly on the progression of coronary atherosclerosis in humans. Suggestive evidence existed from animal studies, especially in primates, that diet and exercise altered atherosclerosis as a result of risk modification. But these animal models did not accurately represent the potential for modifying the coronary atherosclerotic process in humans. Some indirect evidence had been developed in humans by studying arteries more accessible than the coronaries. In the several preliminary studies reported using coronary arteriography to study the impact of risk modification on atherosclerosis, the results had been encouraging but far from definitive. One angiographic follow-up study of vein bypass grafts and severely atherosclerotic coronary arteries reported improvement with lipid lowering therapy. None of these studies had included randomization of patients to systematic, intense, long-term risk reduction versus usual care with prospectively identified coronary artery segments with mild disease.
DESIGN NARRATIVE:
Randomized, fixed-sample. A total of 300 patients were randomized, 155 to usual care (UC) in the community and 145 to special intervention (SI). The SI group received intensive efforts directed at reducing or eliminating risk factors, including lowering LDL-cholesterol and increasing HDL-cholesterol, reducing blood pressure, eliminating cigarette smoking and obesity, increasing exercise, and decreasing stressful life experience. The major endpoint was the rate of coronary artery disease progression as measured by angiography, at baseline and at forty-eight months. Follow-up was for four years.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Men and women, up to 75 years of age. Patients with coronary artery disease but no mechanical intervention on all major vessels.
Treatment and study plan
diet, reducing
BehavioralExercise
Behavioraldiet, fat-restricted
BehavioralSponsors and collaborators
Lead sponsor
Stanford University
Other
Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
Registry information
Important dates
- Study start
- 1983
- Study completion
- 1993
- First posted
- Oct 28, 1999
- Registry last updated
- Jan 12, 2016
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Women's Antioxidant and Folic Acid Cardiovascular Study (WAFACS)
NCT00000541
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsWomen's Angiographic Vitamin and Estrogen Trial (WAVE)
NCT00000555
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsEstrogen Replacement and Atherosclerosis (ERA) in Older Women
NCT00000549
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsEstrogen and Graft Atherosclerosis Research Trial (EAGER)
NCT00000605
Arterial Occlusive Diseases, Arteriosclerosis
View Trial Details